CRISPR Therapeutics AG (NASDAQ: CRSP) is widely recognized as one of the largest and most prominent dedicated gene-editing companies in the biotechnology sector, measured by market capitalization, clinical pipeline maturity, and its historic achievement of securing the world's first regulatory approvals for a CRISPR-based medicine alongside co-developer Vertex Pharmaceuticals.